Shielding design and heat transfer analysis of the transportation container of a hot batch in the Mo production facility.

In molybdenum-99 (Mo) production facilities via the fission method, appropriate transportation containers must be used to transfer irradiated targets from the irradiation facility to the processing facility, following the requirements for transferring radioactive materials. In the Mo production industrial plan of Iran, the transportation container must be capable of carrying a holster containing nine irradiated low-enriched uranium targets, known as a hot batch. In this article, the proper shielding of two-layer containers based on the gamma spectrum emitted from the radioisotope inventory of a local hot batch, including fission products, activation products, and other radioisotopes produced from their decay chains, was investigated by using Monte Carlo code MCNP6.

Investigation of Radiolabeling Efficacy by Enhancement of the Chemical form of no Carrier Added Lu Isolated by Electro Amalgamation Process.

Background: Due to the suitable nuclear decay characteristics, Lu is an attractive radionuclide for various therapeutic applications. The non-carrier added form ofLu has drawn much attention because of its high specific activity needed in radiolabeling studies. There have been several separation methods for NCALu production.

Preparation and Dosimetry Evaluation of a Carrier- Free 90Y Labeled DOTMP as a Promising Agent for Bone Marrow Ablation.

Background And Objective: Skeletal uptake of 90Y-1,4,7,10-tetraazacyclododecane-1,4,7,10- tetramethylene-phosphonate (DOTMP) is used to deliver high doses of this radiopharmaceutical to the bone marrow.

Methods: In this research, carrier-free (c.f.

Preparation, Biological Evaluation and Dosimetry Studies of 175Yb-Bis-Phosphonates for Palliative Treatment of Bone Pain.

Objective: Optimized production and quality control of ytterbium-175 (Yb-175) labeled pamidronate and alendronate complexes as efficient agents for bone pain palliation has been presented.

Methods: Yb-175 labeled pamidronate and alendronate (175Yb-PMD and 175Yb-ALN) complexes were prepared successfully at optimized conditions with acceptable radiochemical purity, stability and significant hydroxyapatite absorption. The biodistribution of complexes were evaluated up to 48 h, which demonstrated significant bone uptake ratios for 175Yb-PAM at all-time intervals.

Preparation and Quality Control of (68)Ga-Citrate for PET Applications.

Objectives: In nuclear medicine studies, gallium-68 ((8)Ga) citrate has been recently known as a suitable infection agent in positron emission tomography (PET). In this study, by applying an in-house produced (68)Ge/(68)Ga generator, a simple technique for the synthesis and quality control of (68)Ga-citrate was introduced; followed by preliminary animal studies.

Methods: (68)GaCl3 eluted from the generator was studied in terms of quality control factors including radiochemical purity (assessed by HPLC and RTLC), chemical purity (assessed by ICP-EOS), radionuclide purity (evaluated by HPGe), and breakthrough.

Production, quality control, and bio-distribution studies of (159)Gd-EDTMP as a palliative agent for bone pain.

Introduction: Particle-emitting, bone-seeking radiopharmaceuticals have attracted the attention of the nuclear medicine community over the last three decades for the treatment of the pain of osteoblastic metastases. The objectives of this research were to produce quality-controlled (159)Gd-EDTMP in order to provide a new therapeutic radiopharmaceutical for use in clinical applications.

Methods: The investigation was an experimental study in which (159)Gd (T1/2=18.

Study of Bone Surface Absorbed Dose in Treatment of Bone Metastases via Selected Radiopharmaceuticals: Using MCNP4C Code and Available Experimental Data.

Bone metastases are major clinical concern that can cause severe problems for patients. Currently, various beta emitters are used for bone pain palliation. This study, describes the process for absorbed dose prediction of selected bone surface and volume-seeking beta emitter radiopharmaceuticals such as (32)P, (89)SrCl2,(90)Y-EDTMP,(153)Sm-EDTMP, (166)Ho-DOTMP, (177)Lu-EDTMP,(186)Re-HEDP, and (188)Re-HEDP in human bone, using MCNP code.

Treatment efficacy of (153)Sm-EDTMP for painful bone metastasis.

Introduction: Involvement of the skeleton can cause an excruciating pain in two-thirds of terminal patients with a history of malignancy. Due to several limitations of other therapies, such as analgesics, bisphosphonates, chemotherapy, hormonal therapy and external beam radiotherapy; bone-seeking radiopharmaceuticals have an important role in palliation of pain from bone metastases. Although these kinds of therapies have many advantages including the ability to treat multiple sites of tumoral involvement simultaneously, no significant confliction with other treatments, ease of administration and the potential to be used repetitively; in Iran using of this modality is not widely practiced.